Presentation from OIS@ASCRS 2016 - Kester Nahen, PhD, Managing Director Video Presentation: https://www.youtube.com/watch?v=2MqL1-bz4JE&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=26

1. Visionary Diagnostic Solutions
Kester Nahen, PhD
Managing Director

2. SPECTRALIS Multimodal Imaging Platform

3. SPECTRALIS
Widefield OCT Module

4. SPECTRALIS Widefield OCT Module
55°30°
16,5 mm

5. SPECTRALIS Widefield OCT Module
Courtesy of Prof. Staurenghi, Milan

6. SPECTRALIS
MultiColor Module

7. MultiColor Imaging
View images of individual laser colors
to gain better understanding of
structural detail at different depths
within the retina
Image courtesy of S. Wolf, MD, PhD, Bern, Switzerland
ERM, RNFL,
macular pigment
blood vessels,
blood, excudates
drusen, RPE,
choroid

8. SPECTRALIS
Widefield Fundus Imaging Module

9. Widefield MultiColor Imaging
30°
55°

10. SPECTRALIS
OCT2 Module

11. Next generation OCT module
85 kHz A-scan rate
Scan time approx. cut in half

12. OCT2 scan speed improves workflow
 OCT2 supports efficient workflow while
performing dense volume scans
 Transverse Section Analysis (TSA)
Vitreoretinal interfaceRPEChoroid

13. OCT2 scan speed improves workflow
 OCT-Angiography
OCT-Angiography - work in progress, not for sale

14. OCT2 scan speed improves workflow
 OCT2 supports comprehensive
scan protocols
 Glaucoma Module Premium Edition
Glaucoma Module Premium Edition is pending FDA approval

15. OCT2 image quality improves diagnostic potential
High image contrast vitreous to choroid

16. Reliable Multi-Layer Segmentation
OCT2
Foundation for
 Layer thickness analysis
 Transverse Section Analysis (TSA)
 OCT-Angiography
OCT-Angiography - work in progress, not for sale
GCL

17. OCT2 image quality improves diagnostic potential
Transverse Section Analysis
of patient with drusen

18. OCT2 integrates with existing SPECTRALIS
OCT
OCT2
 Analyses are fully
compatible between
both OCT generations
 Ensures tracking
progression over long
periods of time using
AutoRescan function
and Active Eye
Tracking

19. OCT2 integrates with existing SPECTRALIS
OCT
OCT2
SPECTRALIS
 Analyses are fully
compatible between
both OCT generations
 Ensures tracking
progression over long
periods of time using
AutoRescan function
and Active Eye
Tracking
 Makes the Spectralis
a safe long term
investment

20. SPECTRALIS
OCT-Angiography Module
OCT-Angiography is work in progress

21. Superficial Capillary
Plexus
Depth-Selective Visualization of the Vascular Network
OCT-Angiography is work in progress

22. Superficial Capillary
Plexus
Depth-Selective Visualization of the Vascular Network
OCT-Angiography is work in progress

23. Deep Capillary
Plexus
Depth-Selective Visualization of the Vascular Network
OCT-Angiography is work in progress

24. Deep Capillary
Plexus
Depth-Selective Visualization of the Vascular Network
OCT-Angiography is work in progress

25. Choriocapillaris
Depth-Selective Visualization of the Vascular Network
OCT-Angiography is work in progress

26. 26
Sattler’s Layer
Depth-Selective Visualization of the Vascular Network
OCT-Angiography is work in progress

27. 27
Haller’s Layer
Depth-Selective Visualization of the Vascular Network
OCT-Angiography is work in progress

28. FA
BluePeak
ICGA
OCT Angio
OCT-Angiography is work in progress
SPECTRALIS
Multimodal
Imaging

29. FA
BluePeak
ICGA
OCT Angio
SPECTRALIS
Multimodal
Imaging
OCT-Angiography is work in progress

30. FA
BluePeak
ICGA
OCT Angio
OCT-Angiography is work in progress
SPECTRALIS
Multimodal
Imaging

31. FA
BluePeak
ICGA
OCT Angio
SPECTRALIS
Multimodal
Imaging
OCT-Angiography is work in progress

32. FA
BluePeak
ICGA
OCT Angio
OCT-Angiography is work in progress
SPECTRALIS
Multimodal
Imaging

33. FA
BluePeak
ICGA
OCT Angio
SPECTRALIS
Multimodal
Imaging
OCT-Angiography is work in progress

34. FA
BluePeak
ICGA
OCT Angio
OCT-Angiography is work in progress
SPECTRALIS
Multimodal
Imaging

35. SPECTRALIS – Expandable Imaging Platform
 Explore New SPECTRALIS Modules
 Widefield OCT
 Widefield Fundus Imaging
 OCT2
 OCT-Angiography
 Enjoy Safe Investment
 SPECTRALIS systems purchased with Advanced
Upgrade Package or MultiColor module are
upgradeable to OCT2
OCT-Angiography is work in progress

36. For 25 years Heidelberg Engineering
has been providing solutions
to fundamental diagnostic challenges
in ophthalmology.
With HRT and SPECTRALIS
we have achieved this
for both glaucoma and retina.
The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

37. Now we intend to achieve the same
for the current challenges in the field of
cataract and refractive surgery.
The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

38. Cataract Refractive Imaging Platform
Swept-Source OCT Technology
All measurements and analysis are
based on high-resolution diagnostic images
High confidence in measurements
The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

39. Modular Platform
 Biometry for IOL calculation
 Corneal topography/tomography
 Anterior segment biometry
 Anterior segment imaging
All in one device
All based on swept-source OCT
The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

40. Workflow Optimization
Current challenge
Heidelberg Engineering solution
The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

41. Image Management and Device Integration
The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

42. SPECTRALIS OCT on Board ISS
THANK YOU!

43. DIAGNOSTICS-IMPACT ON THE PREMIUM
CHANNEL: PANEL DISCUSSION
Richard Lindstrom, MD
Moderated By:
Tom Frinzi
President – AMO
SVP – Abbott Laboratories
Participants:
Dave Harmon
President
Market Scope
Warren Hill, MD
Ludwin Monz, PhD
President & CEO
Carl Zeiss Meditec AG
Jay Pepose, MD, PhD Vance Thompson, MD

44. How important are preoperative diagnostics
in managing the premium channel IOL
patients?

45. How large is the market opportunity in
preoperative diagnostics.

46. Are there significant unmet needs
in this arena?

47. Are you seeing significant investment
occurring by industry, including your own
company, to meet these unmet needs.
Can one get a good return on investment in
diagnostic equipment.

48. If time: Do you see a need in the future
for companies to pair diagnostics with
therapeutics as a package offering?